tenofovir disoproxil fumarate / Generic mfg. - LARVOL DELTA

The blocking efficacy and safety of tenofovir disoproxil fumarate tablets on mother-to-child transmission in pregnant women with high serum HBV DNA load: a retrospective cohort study. (PubMed, BMC Pregnancy Childbirth) - "TDF tablets can prevent MTCT of HBV in pregnant women with high HBV DNA loads. The treatment increases the seroconversion rates of HBV DNA, HBeAg, and HBsAg in mothers and infants, and shows a favorable safety profile without severe adverse outcomes."

Journal • Retrospective data • Hepatitis B • Infectious Disease • Inflammation

Modelling Micro-Elimination: Third-Trimester Tenofovir Prophylaxis for Perinatal Transmission of Hepatitis B in the Remote Dolpa District of Nepal. (PubMed, J Viral Hepat) - "Using mathematical modelling, we evaluated the impact of third-trimester tenofovir disoproxil fumarate (TDF) prophylaxis on HBV burden and estimated the time required to achieve HBV elimination in Dolpa...In geographically inaccessible settings, a micro-elimination approach using third-trimester TDF is an effective and equitable strategy for HBV control. This approach is likely to substantially reduce HBV burden and HBV-related mortality even before achieving elimination, while also addressing some of the challenges of immunoprophylaxis."

Journal • Hepatitis B • Infectious Disease • Inflammation

Different nucleos(t)ide analogs in resected hepatitis B virus-associated hepatocellular carcinoma: a systematic review. (PubMed, Front Pharmacol) - "Compared with the control group, antiviral therapies using telbivudine (HR [95% CrI] = 0.23 [0.12,0.44]), tenofovir disoproxil fumarate (HR [95% CrI] = 0.40 [0.30,0.52]), lamivudine (HR [95% CrI] = 0.50 [0.34, 0.75]), adefovir (HR [95% CrI] = 0.55 [0.38,0.79]), and entecavir (HR [95% CrI] = 0.55 [0.43,0.71]) significantly improved OS...When compared to other nucleos(t)ide analogs, telbivudine and tenofovir disoproxil fumarate exhibited the most notable effects. Identifier CRD42024612794."

Journal • Review • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Electrospun Tenofovir/Emtricitabine-Zein Nanofibers for Pre-Exposure Prophylaxis Platform against HIV through Vaginal Delivery. (PubMed, ACS Omega) - "Pre-exposure prophylaxis (PrEP) using tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is a strategy recommended by the World Health Organization to prevent sexual transmission of HIV...The release studies showed controlled release of TDF and FTC for 24 h. Zein-based hybrid nanofibers incorporating mucoadhesive polymers represent a promising drug delivery system for the vaginal delivery of antiretroviral drugs as an effective and patient-compliant strategy for HIV prevention. This study provides a comprehensive formulation approach, combining zein with poly-(ethylene oxide) and polyvinylpyrrolidone to fine-tune nanofiber morphology, mechanical strength, mucoadhesion, and drug release properties for vaginal delivery."

Journal • Human Immunodeficiency Virus • Infectious Disease

Dapagliflozin treatment ameliorates oxidative stress, apoptosis and inflammation in tenofovir-induced nephrotoxicity in rats. (PubMed, Sci Rep) - "Tenofovir disoproxil fumarate is a widely prescribed component in antiretroviral therapy regimes frequently associated with nephrotoxicity. Furthermore, dapagliflozin treatment reduced inflammatory response and apoptotic cell death, marked by increased Bcl-2 expression and decreased levels of TLR4, NF-κB, pro-inflammatory cytokines, Bax, cytochrome c, and caspase-3. Dapagliflozin holds multifaceted renoprotective effects potentially offering a therapeutic strategy to slow the progression of kidney injury in tenofovir-induced nephrotoxicity."

IO biomarker • Journal • Preclinical • Inflammation • Renal Disease • BCL2 • CASP3 • TLR4

Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy. (PubMed, United European Gastroenterol J) - P2 | "The long-term follow-up of this large randomised clinical trial demonstrates that combination therapy with TDF and virological response to PEG-IFNα-2a (undetectable HDV RNA and HBsAg loss) were associated with better clinical outcomes."

Clinical data • Journal • Fibrosis • Immunology • Inflammation • Liver Failure • IFNA1

Real-World Effectiveness of Antiviral Prophylaxis for Preventing Hepatitis B Virus (HBV) Reactivation in Patients Undergoing Immunosuppressive Therapy. (PubMed, Viruses) - "Prophylaxis consisted of entecavir in 76.4%, tenofovir alafenamide in 13.1%, and tenofovir disoproxil fumarate in 10.5%. HBV reactivation occurred in only one patient, who had discontinued treatment. These findings emphasize the importance of HBV screening and timely prophylactic antiviral therapy in patients undergoing immunosuppression to effectively prevent HBV reactivation."

Journal • Real-world evidence • Retrospective data • Hepatitis B • Infectious Disease • Inflammation

Narrative Review on Parathyroid Gland Disorders in Individuals Living with HIV: An Update. (PubMed, Metabolites) - "HIV infection, combined antiretroviral therapy (cART), and immune activation contribute to parathyroid dysfunction, with cART regimens, particularly Tenofovir Disoproxil Fumarate (TDF), exacerbating these disturbances by altering the calcium and parathyroid hormone (PTH) dynamics...Early detection of subclinical parathyroid dysfunction can prevent complications such as secondary hyperparathyroidism and neuromuscular symptoms. Clinicians should be aware of atypical biochemical presentations, such as elevated PTH with normal calcium, which may indicate cART-induced dysregulation, improving patient management and outcomes."

Journal • Review • Endocrine Cancer • Endocrine Disorders • Human Immunodeficiency Virus • Hypoparathyroidism • Infectious Disease • Musculoskeletal Diseases • Oncology • Orthopedics • Secondary Hyperparathyroidism

Assessment of the risk of discontinuation of tenofovir disoproxil fumarate after delivery and the benefit of continued treatment in patients with immune tolerance. (PubMed, Front Med (Lausanne)) - "There were no significant differences in the average eGFR and serum phosphorus levels between the two groups from baseline to 144 weeks after TDF treatment. Postpartum discontinuation of TDF poses significant risks for immunotolerant pregnant women, whereas continuing TDF treatment for 144 weeks postpartum demonstrates favorable antiviral efficacy, bone and renal safety profiles."

Journal • Hepatitis B • Infectious Disease • Inflammation

Comparative Renal Safety of Besifovir Dipivoxil Maleate and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients: Insights From a Nationwide Cohort Study. (PubMed, J Korean Med Sci) - "BSV is linked to a lower incidence of CKD than TDF, particularly in patients aged 60 and older, suggesting BSV may be a safer treatment option in elderly patients at high risk of renal impairment."

Clinical • Journal • Retrospective data • Chronic Kidney Disease • Hepatitis B • Infectious Disease • Inflammation • Nephrology • Renal Disease

Cardiovascular and Renal Effects of Physical Training in Male Rats Under Tenofovir Disoproxil Fumarate Treatment (AHA 2025) - "TDF treatment impaired blood pressure, renal blood flow, renal function and increased oxidative stress. Moderate physical training showed renoprotective effects, improving tubular function and reducing oxidative damage and hemodinamic profile."

Preclinical • Acute Kidney Injury • Cardiovascular • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Nephrology • Renal Disease • CAT • LCN2

Adherence to Oral HIV Pre-exposure Prophylaxis During Pregnancy and the Post-partum Period: Lessons Learned in an Open-Labelled Clinical Trial. (PubMed, AIDS Behav) - P2/3 | "In an open-label PrEP clinical trial, adherence to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) was measured using returned pill counts during pregnancy and post-delivery, up to 54 weeks. Based on TFV-DP levels, only 20% of pregnant women and 10% of postpartum women had levels suggestive of adherence greater than 80%. Lack of transparency in adherence disclosure underscores the need for real-time, objective measures of adherence to inform targeted adherence counseling.Clinical Trial Number CAP016 is on ClinicalTrials.gov ( https://clinicaltrials.gov/ct2/show/NCT03227731 )."

Journal • Human Immunodeficiency Virus • Infectious Disease

Postpartum Hepatitis B Exacerbation Following Discontinuation of Nucleotide Analogue Therapy: A Case Report. (PubMed, Intern Med) - "A woman in her 20s from Vietnam, an asymptomatic hepatitis B virus (HBV) carrier with a high viral load, was initiated on tenofovir disoproxil fumarate (TDF) at 31 weeks of gestation. TDF was discontinued after delivery; however, at eight weeks postpartum, she developed an acute exacerbation of hepatitis, characterized by elevated ALT levels and HBV DNA rebound. Although the risk of hepatitis flares following TDF discontinuation is generally considered low, this case highlights the potential for severe postpartum exacerbation and underscores the importance of considering continued antiviral therapy in the postpartum period."

Journal • Hepatitis B • Hepatitis C • Infectious Disease • Inflammation

Spectrum of Biopsy-Proven Kidney Diseases in People with HIV in the Modern Era: The Bronx Experience (KIDNEY WEEK 2025) - "TID was more common in those receiving tenofovir disoproxil fumarate (33%)...Histologic patterns are influenced by ART use, viral suppression and comorbidity burden. These findings support the role of biopsy in diagnosis and management of PWH with kidney disease."

Biopsy • Cardiovascular • Chronic Kidney Disease • Diabetic Nephropathy • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Renal Disease • CD4

Albuminuria Testing and Prevalence in a Clinic-Based Cohort of People with HIV in the Bronx (KIDNEY WEEK 2025) - "A logistic regression model estimated the probability of testing, adjusting for demographic (age, sex, race, smoking, illicit drugs), hypertension, diabetes, cardiovascular disease, eGFR, HIV-related factors (CD4, viral load, tenofovir disoproxil fumarate (TDF)), and nephrology care...Conclusion Albuminuria was prevalent among PWH but often underrecognized due to lack of testing. These findings highlight the need for improved implementation of albuminuria screening in this high-risk population."

Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • CD4

Dual Burden of HIV Infection and Aging on Kidney Function and Skeletal Health (KIDNEY WEEK 2025) - "Clinical data collected included duration since HIV diagnosis and use of tenofovir disoproxil fumarate (TDF)...Conclusion Older PLWH exhibit a high prevalence of CKD and CKD-associated osteoporosis, placing them at elevated risk for fragility fractures. These findings highlight the critical need for more comprehensive and targeted screening strategies within this population to enhance early detection and optimize management of these comorbid conditions."

Chronic Kidney Disease • Diabetes • Endocrine Disorders • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Liver Failure • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Renal Disease • Rheumatology

Early maternal tenofovir treatment and infant vaccination: a scalable model for hepatitis B virus mother-to-child transmission control in resource-limited areas. (PubMed, Transl Gastroenterol Hepatol) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation

Tenofovir Disoproxil Fumarate for the Prevention of Hepatitis B Virus Reactivation during Chemoimmunotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter Clinical Trial (ChiCTR) - P2 | N=49 | Recruiting | Sponsor: Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University; Jiangsu Province Hospital, The First Affiliated Hospital of Na

New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hepatitis B • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083. (PubMed, Open Forum Infect Dis) - "HIV phenotyping confirmed that the transmitted virus had DTG and 3TC resistance but retained susceptibility to DTG at higher drug concentrations. Pharmacologic testing indicated that the DTG concentrations observed in this case were sufficient to overcome the effects of 2 major baseline INSTI resistance mutations (G140S and Q148H)."

Journal • Human Immunodeficiency Virus • Infectious Disease

Urinary Exosome-Derived microRNAs as Biomarkers of Tenofovir Disoproxil Fumarate (TDF)-Induced Renal Toxicity in People with HIV-1. (PubMed, Int J Antimicrob Agents) - "Urinary exosome-derived miRNAs demonstrate their potential as early, non-invasive biomarkers for detecting and predicting TDF-associated renal dysfunction in PWH, potentially enabling earlier clinical intervention before irreversible damage occurs."

Biomarker • Journal • Chronic Kidney Disease • Human Immunodeficiency Virus • Infectious Disease • Nephrology • Renal Disease • MIR127 • MIR203A • MIR23A • MIR29A • MIR423

Evaluation of serum phosphorus levels and their relation with the development of osteoporosis in people living with HIV/AIDS. (PubMed, Rev Assoc Med Bras (1992)) - "Hypophosphatemia was significantly associated with male gender, prolonged infection, and the use of antiretroviral therapy, especially regimens with tenofovir disoproxil fumarate. There was no statistical correlation between hypophosphatemia and osteoporosis, but female gender and advanced age were risk factors for the latter. These findings highlight the importance of monitoring bone and kidney parameters in people living with HIV, especially those on long-term tenofovir disoproxil fumarate, with a view to more effective preventive and therapeutic strategies."

Journal • Human Immunodeficiency Virus • Infectious Disease • Osteoporosis • Renal Disease • Rheumatology

The impact of long-term potent antiviral therapy on the natural course of disease in patients with hepatitis B virus-related cirrhosis. (PubMed, Hepatol Forum) - "Potent antiviral treatment effectively maintained VR in the long-term follow-up of patients with HBV-related cirrhosis. HCC may still develop, albeit at a lower rate in these patients."

Journal • Fibrosis • Hepatitis B • Hepatocellular Cancer • Immunology • Infectious Disease • Inflammation • Oncology • Solid Tumor

Long Term Trends For Bone Mineral Density and Trabecular Bone Scores In Men Living With and Without HIV: Impact of Tenofovir Disoproxil Fumarate Exposure (EACS 2025) - "TDF exposure was positively associated with BMD changes. This suggests that neither BMD nor TDF exposure are adequate predictors of fracture risk."

Human Immunodeficiency Virus • Infectious Disease

Long-term viral suppression, and cardiometabolic benefits of switch to ainuovirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open-label results from the SPRINT post-study (EACS 2025) - "Purpose : In the previous 96-week results of the SPRINT extensional study, switch to ainuovirine, a new-generation NNRTI, coformulated with lamivudine, and tenofovir DF (ANV/3TC/TDF) maintained viral suppression (VS), and improved cardiometabolic conditions among people with HIV-1 (PWH) switching from both classical NNRTI-based regimens, and E/C/F/TAF. The accompanied safety benefits included persistent improvement in LDL-C level, and ASCVD risk strata. Renal function remained stable among this population, and required general routine monitoring."

Clinical • Human Immunodeficiency Virus • Infectious Disease • CD4

Long-term Lipid Metabolism Benefits of Switching to Ainuovirine-based Regimen in People with HIV-1: 144-Week Results from the SPRINT Extensional Post-study (EACS 2025) - "Purpose : This post-hoc analysis of the SPRINT extensional post-study aimed to evaluate the 144-week lipid profile changes in virologically suppressed people with HIV-1 (PWH) who switched to ainuovirine/lamivudine/tenofovir DF (ANV/3TC/TDF) from either NNRTI- or boosted INSTI-based regimens, with particular focus on its potential to reverse INSTI-associated dyslipidemia. Method : In this open-label extensional post-study, 723 out of 762 originally randomized participants (364 continuing ANV/3TC/TDF; 359 switching from E/C/F/TAF) were followed up for through weeks...Similar significant improvements were observed for non-HDL-C (-0.62 mmol/L, -0.72 to -0.52), total cholesterol (-0.77 mmol/L, -0.87 to -0.67), and triglycerides (-0.63 mmol/L, -1.00 to -0.26) from week 48. Conclusions : ANV/3TC/TDF regimen improved lipid safety profile remarkably in virologically suppressed people with HIV-1, with a special beneficial potential for people previously exposed to INSTI-based..."

Human Immunodeficiency Virus • Infectious Disease